Hematological malignancies with t(9;11)(p21-22;q23) - A laboratory and clinical study of 125 cases

G. J. Swansbury, R. Slater, B. J. Bain, Anthony Moorman, L. M. Seeker-Walker

Research output: Contribution to journalArticle

Abstract

This paper reports clinical and cytogenetic data from 125 cases with t(9;11)(p21-22;q32) which were accepted for a European Union Concerted Action Workshop on 11q23. This chromosome abnormality is known to occur predominantly in acute myeloid leukemia (AML) FAB type M5a and less often in AML M4; in this series it was also found to occur, uncommonly, in other AML FAB types, in childhood acute lymphoblastic leukemia (ALL) (nine cases), in relatively young patients with myelodysplastic syndrome (MDS) (five cases), acute biphenotypic leukemia (two cases), and acute undifferentiated leukemia (one case). All age groups were represented but 50% of the patients were aged less than 15 years. The t(9;11) was the sole abnormality in 57 cases with AML; trisomy 8 was the most common additional abnormality (23 cases, including seven with further abnormalities), and 28 cases had other additional abnormalities. Among the t(g;11)+ve patients with AML, the white cell count (WBC) and age group were significant predictors of event-free survival; central nervous system (CNS) involvement or karyotype class (sole, with trisomy 8, or with other), also contributed to prognosis although our data could not show these to be independent factors. The best outcome was for patients aged 1-9 years, with low WBC, and with absence of CNS disease or presence of trisomy 8. For patients aged less than 15 years, the event-free survival for ALL patients was not significantly worse than that of AML patients.

Original languageEnglish (US)
Pages (from-to)792-800
Number of pages9
JournalLeukemia
Volume12
Issue number5
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

Fingerprint

Hematologic Neoplasms
Acute Myeloid Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Disease-Free Survival
Biphenotypic Acute Leukemia
Age Groups
Leukemia, Myelomonocytic, Acute
Central Nervous System Diseases
Myelodysplastic Syndromes
European Union
Clinical Studies
Karyotype
Cytogenetics
Chromosome Aberrations
Leukemia
Central Nervous System
Cell Count
Education
Trisomy Chromosome 8

Keywords

  • Cytogenetics
  • Leukemia
  • MLL
  • t(9;11)

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Hematological malignancies with t(9;11)(p21-22;q23) - A laboratory and clinical study of 125 cases. / Swansbury, G. J.; Slater, R.; Bain, B. J.; Moorman, Anthony; Seeker-Walker, L. M.

In: Leukemia, Vol. 12, No. 5, 01.01.1998, p. 792-800.

Research output: Contribution to journalArticle

Swansbury, G. J. ; Slater, R. ; Bain, B. J. ; Moorman, Anthony ; Seeker-Walker, L. M. / Hematological malignancies with t(9;11)(p21-22;q23) - A laboratory and clinical study of 125 cases. In: Leukemia. 1998 ; Vol. 12, No. 5. pp. 792-800.
@article{c947fdb03ede45888cf77bdad44d9e34,
title = "Hematological malignancies with t(9;11)(p21-22;q23) - A laboratory and clinical study of 125 cases",
abstract = "This paper reports clinical and cytogenetic data from 125 cases with t(9;11)(p21-22;q32) which were accepted for a European Union Concerted Action Workshop on 11q23. This chromosome abnormality is known to occur predominantly in acute myeloid leukemia (AML) FAB type M5a and less often in AML M4; in this series it was also found to occur, uncommonly, in other AML FAB types, in childhood acute lymphoblastic leukemia (ALL) (nine cases), in relatively young patients with myelodysplastic syndrome (MDS) (five cases), acute biphenotypic leukemia (two cases), and acute undifferentiated leukemia (one case). All age groups were represented but 50{\%} of the patients were aged less than 15 years. The t(9;11) was the sole abnormality in 57 cases with AML; trisomy 8 was the most common additional abnormality (23 cases, including seven with further abnormalities), and 28 cases had other additional abnormalities. Among the t(g;11)+ve patients with AML, the white cell count (WBC) and age group were significant predictors of event-free survival; central nervous system (CNS) involvement or karyotype class (sole, with trisomy 8, or with other), also contributed to prognosis although our data could not show these to be independent factors. The best outcome was for patients aged 1-9 years, with low WBC, and with absence of CNS disease or presence of trisomy 8. For patients aged less than 15 years, the event-free survival for ALL patients was not significantly worse than that of AML patients.",
keywords = "Cytogenetics, Leukemia, MLL, t(9;11)",
author = "Swansbury, {G. J.} and R. Slater and Bain, {B. J.} and Anthony Moorman and Seeker-Walker, {L. M.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1038/sj.leu.2401014",
language = "English (US)",
volume = "12",
pages = "792--800",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Hematological malignancies with t(9;11)(p21-22;q23) - A laboratory and clinical study of 125 cases

AU - Swansbury, G. J.

AU - Slater, R.

AU - Bain, B. J.

AU - Moorman, Anthony

AU - Seeker-Walker, L. M.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - This paper reports clinical and cytogenetic data from 125 cases with t(9;11)(p21-22;q32) which were accepted for a European Union Concerted Action Workshop on 11q23. This chromosome abnormality is known to occur predominantly in acute myeloid leukemia (AML) FAB type M5a and less often in AML M4; in this series it was also found to occur, uncommonly, in other AML FAB types, in childhood acute lymphoblastic leukemia (ALL) (nine cases), in relatively young patients with myelodysplastic syndrome (MDS) (five cases), acute biphenotypic leukemia (two cases), and acute undifferentiated leukemia (one case). All age groups were represented but 50% of the patients were aged less than 15 years. The t(9;11) was the sole abnormality in 57 cases with AML; trisomy 8 was the most common additional abnormality (23 cases, including seven with further abnormalities), and 28 cases had other additional abnormalities. Among the t(g;11)+ve patients with AML, the white cell count (WBC) and age group were significant predictors of event-free survival; central nervous system (CNS) involvement or karyotype class (sole, with trisomy 8, or with other), also contributed to prognosis although our data could not show these to be independent factors. The best outcome was for patients aged 1-9 years, with low WBC, and with absence of CNS disease or presence of trisomy 8. For patients aged less than 15 years, the event-free survival for ALL patients was not significantly worse than that of AML patients.

AB - This paper reports clinical and cytogenetic data from 125 cases with t(9;11)(p21-22;q32) which were accepted for a European Union Concerted Action Workshop on 11q23. This chromosome abnormality is known to occur predominantly in acute myeloid leukemia (AML) FAB type M5a and less often in AML M4; in this series it was also found to occur, uncommonly, in other AML FAB types, in childhood acute lymphoblastic leukemia (ALL) (nine cases), in relatively young patients with myelodysplastic syndrome (MDS) (five cases), acute biphenotypic leukemia (two cases), and acute undifferentiated leukemia (one case). All age groups were represented but 50% of the patients were aged less than 15 years. The t(9;11) was the sole abnormality in 57 cases with AML; trisomy 8 was the most common additional abnormality (23 cases, including seven with further abnormalities), and 28 cases had other additional abnormalities. Among the t(g;11)+ve patients with AML, the white cell count (WBC) and age group were significant predictors of event-free survival; central nervous system (CNS) involvement or karyotype class (sole, with trisomy 8, or with other), also contributed to prognosis although our data could not show these to be independent factors. The best outcome was for patients aged 1-9 years, with low WBC, and with absence of CNS disease or presence of trisomy 8. For patients aged less than 15 years, the event-free survival for ALL patients was not significantly worse than that of AML patients.

KW - Cytogenetics

KW - Leukemia

KW - MLL

KW - t(9;11)

UR - http://www.scopus.com/inward/record.url?scp=0031953952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031953952&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2401014

DO - 10.1038/sj.leu.2401014

M3 - Article

C2 - 9593283

AN - SCOPUS:0031953952

VL - 12

SP - 792

EP - 800

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -